PD-1抑制剂卡瑞利珠单抗在晚期恶性肿瘤中的应用进展

Application of PD-1 inhibitor Camrelizumab in advanced malignancies

随着以肿瘤免疫检查点为靶点的治疗取得令人瞩目的成果,愈来愈多的新型免疫治疗药物得以研发并应用于恶性肿瘤治疗领域。卡瑞利珠单抗(艾瑞卡)是一种新型人源化免疫球蛋白G4(IgG4)型单克隆抗体(mAb),可靶向结合程序性死亡分子1(PD-1),并阻断其与程序性死亡分子配体1(PD-L1)的结合,从而恢复机体的免疫功能,以达到抗肿瘤的作用。该药于2019年5月29日正式获得国家药品监督管理局(NMPA)的批准,用于至少经过二线系统治疗的复发或难治性经典型霍奇金淋巴瘤(cHL)的治疗。此外,该药在食管鳞状细胞癌(ESCC)、肝细胞癌(HCC)、鼻咽癌(NPC)、非小细胞肺癌(NSCLC)、胃癌(GC)及胃食管交界癌(EGJC)等恶性肿瘤中均表现出良好的抗肿瘤活性。该文就卡瑞利珠单抗的作用机制、药效学与药动学、临床研究、不良反应等方面的进展进行综述。

With the remarkable achievements made in the treatment targeted at tumor immune checkpoints,more and more new immunotherapy drugs have been applied to the malignancies treatment.Camrelizumab(AiRuiKa)is a novel human immunoglobulin G4(IgG4)monoclonal antibody(mAb),which can target the programmed death 1(PD-1)and block its binding to the programmed death ligand 1(PD-L1),so as to restore the body's immune function and achieve anti-tumor effect.The drug was officially approved by National Medical Products Administration(NMPA)on May 29,2019 for use in patients with recurrent or refractory classical Hodgkin's lymphoma(cHL)who are treated with at least second-line systemic therapy.In addition,the drug showed good anti-tumor activity in esophageal squamous cell carcinoma(ESCC),hepatocellular carcinoma(HCC),nasopharyngeal carcinoma(NPC),non-small cell lung cancer(NSCLC),and gastric cancer(GC)and gastroesophageal junction cancer(EGJC).The research progress of camrelizumab on mechanism of action,pharmacodynamics and pharmacokinetics,clinical studies,adverse reactions etc.were reviewed in present paper.